AG-13958

• CAT Number: I001401
• CAS Number: 319460-94-1
• Molecular Formula: C26H22FN7O
• Molecular Weight: 467.50
• Purity: ≥95%
• Synonyms: N-[2-fluoro-5-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]amino]phenyl]-2,5-dimethylpyrazole-3-carboxamide
• InChI: InChI=1S/C26H22FN7O/c1-16-13-25(34(2)33-16)26(35)30-24-15-19(7-10-21(24)27)29-18-6-9-20-22(31-32-23(20)14-18)11-8-17-5-3-4-12-28-17/h3-15,29H,1-2H3,(H,30,35)(H,31,32)/b11-8+
• InChIKey: JXSVVZKPEDIRTN-DHZHZOJOSA-N
• SMILES: CC1=NN(C(=C1)C(=O)NC2=C(C=CC(=C2)NC3=CC4=C(C=C3)C(=NN4)/C=C/C5=CC=CC=N5)F)C

AG-13958（Cat No.:I001401）is a potent oral aldose reductase inhibitor (ARI) developed for the treatment of diabetic complications. Aldose reductase, a key enzyme in the polyol pathway, converts glucose into sorbitol, which accumulates under hyperglycemic conditions and contributes to oxidative stress and tissue damage. By blocking this enzyme, AG-13958 helps prevent sorbitol buildup, thereby protecting nerves, lenses, and vascular tissues. Preclinical and clinical studies demonstrated its ability to reduce diabetic neuropathy and retinopathy risk, highlighting its therapeutic potential in managing long-term complications of diabetes mellitus.